|
May 9
|
Telesis Bio Reports First Quarter 2024 Financial Results
|
|
May 6
|
Telesis Bio Announces Reverse Stock Split
|
|
Apr 18
|
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
|
|
Mar 28
|
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Aug 29
|
Telesis Bio Appoints William J. Kullback Chief Financial Officer
|
|
May 23
|
Telesis Bio to Present at SynBioBeta 2023
|
|
May 22
|
Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit
|